Orange Book product · Generic (ANDA)
TAZAROTENE
TAZAROTENE
At a glance
Mar 10, 2025
Approved
Generic (ANDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Mar 10, 2025
1 yr 4 mo ago
Today
Pharmaceutical detail
Active ingredient
TAZAROTENE
Strength
0.05%
Dosage form
CREAM
Route
TOPICAL
TE code
AB
Application
ANDA 208662
Product number
002
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of TAZAROTENE
- 2019ARAZLOBrand (NDA)
NDA 211882 · BAUSCH
- 2012FABIORBrand (NDA)
NDA 202428 · MAYNE PHARMA
- 2002AVAGEBrand (NDA)
NDA 021184 · ALMIRALL
- 1997TAZORACBrand (NDA)
NDA 020600 · ALMIRALL
- 2025TAZAROTENEGeneric (ANDA)
ANDA 214560 · SOLARIS PHARMA CORP
- 2025TAZAROTENEGeneric (ANDA)
ANDA 215393 · PADAGIS ISRAEL
- 2024TAZAROTENEGeneric (ANDA)
ANDA 217075 · PADAGIS ISRAEL
- 2023TAZAROTENEGeneric (ANDA)
ANDA 213079 · PADAGIS ISRAEL
- 2023TAZAROTENEGeneric (ANDA)
ANDA 213644 · SOLARIS PHARMA CORP
- 2022TAZAROTENEGeneric (ANDA)
ANDA 215433 · COSETTE PHARMS NC
- 2022TAZAROTENEGeneric (ANDA)
ANDA 214136 · COSETTE PHARMS NC
- 2019TAZAROTENEGeneric (ANDA)
ANDA 211175 · FOUGERA PHARMS INC
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
